Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy

Cancer statistics, 2022

Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials

Richard Sylvester, Adrian P.M. van der Meijden, Willem Oosterlinck et al. · European Urology · 2006 · 3K citations

Medicine, Oncology, Urology +10

Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology

Ahmad Shabsigh, Ruslan Korets, Kinjal Vora et al. · European Urology · 2008 · 1.4K citations

Medicine, Surgery, Urology +12

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

Donald L. Lamm, Brent A. Blumenstein, John D. Crissman et al. · The Journal of Urology · 2000 · 1.3K citations

Medicine, Oncology, Urology +11

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni et al. · The Lancet Oncology · 2021 · 533 citations · Full text

Medicine, Oncology, Pharmacotherapy +12